Vanta Bioscience Ltd Share Price & Stock Analysis

Vanta Bioscience Ltd (BSE: 540729) is a Secunderabad, Telangana-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹0 Cr, it ranks #6,158 by market cap among the 6,197 Indian listed companies on FinBizNet, and #10 of 10 in Life Sciences Tools and Services. At ₹18.00 (as of 19 Nov 2026), the share price is 31.4% below its 52-week high of ₹26.22 and 22.4% above its 52-week low of ₹14.71. The share price is down 31.4% over one year and down 8.4% over three months.

Key Metrics

Current Price₹18.00
Market Cap₹0 Cr
BSE Code540729
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services
Sub-IndustryLife Sciences Tools and Services
P/E Ratio132.3
Return on Equity0.87%
Return on Assets0.64%
52-Week Range₹14.71 – ₹26.22
1-Year Price Change-31.4%
3-Month Price Change-8.4%
Beta (1Y)0.18
HeadquartersSecunderabad, Telangana
Websitewww.vantabio.com

Shareholding and Delivery

Delivery averaged 83.7% of traded volume across 7 BSE sessions (30 Oct 2026 – 17 Nov 2026).

About Vanta Bioscience Ltd

Vanta Bioscience Limited, together with its subsidiaries, operates as a preclinical contract research organization in India. The company offers a range of services in method development, validation, impurity profiling, impurity isolation, characterization, certification and evaluation, mammalian and genetic toxicology, drug metabolism, pharmacokinetics, and bio-analysis during the preclinical stage of drug development. It also provides testing services for agrochemicals and chemicals, such as physico-chemical testing; sub-acute, sub-chronic, and chronic; toxicokinetics assessment, CoA and dose formulation analysis, 5 batch analysis, and studies on behavior in water, soil and air, bioaccumulation, as well as acute 6 pack, carcinogenicity, genetic toxicity, DART, eco-toxicity, and alternative to animal studies. In addition, it offers diet formulation services, which include starter material processing, proximate and composition analysis, diet balancing and formulation, irradiation, and p

Products and Services

1. Full Service Preclinical Contract Research Organization-This segment operates as a preclinical contract research organization. It offers preclinical safety assessment services for clients from pharmaceutical, medical device, nutraceutical, feed additive, biotech, agrochemical, cosmetic, and chemical industries.

Business Segments

1. Full Service Preclinical Contract Research Organization-100%

Vanta Bioscience Ltd vs Peers — Life Sciences Tools and Services

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Indegene Ltd₹14,840 Cr40.213.94%₹1,122 Cr+26.1%
Suven Life Sciences Ltd.₹7,951 Crn/m-78.80%₹1 Cr+51.8%
Vimta Labs Ltd₹2,259 Cr29.518.55%₹112 Cr-26.8%
Tarsons Products Limited₹1,730 Cr114.92.26%₹124 Cr+25.7%
Brooks Laboratories Ltd.₹198 Cr7.922.28%₹19 Cr-34.2%
Bilcare Ltd.₹194 Cr108.3-5.21%——
Jeevan Scientific Technology Ltd₹176 Cr129.41.68%—+42.3%
Vivo Bio Tech Ltd.₹37 Crn/m-2.00%₹14 Cr-55.7%
Vanta Bioscience Ltd₹0 Cr132.30.87%—-31.4%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Vanta Bioscience Ltd?

Vanta Bioscience Ltd is trading at ₹18.00, with a market capitalisation of ₹0 Cr.

Which sector does Vanta Bioscience Ltd belong to?

Vanta Bioscience Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).

What are the key financial ratios of Vanta Bioscience Ltd?

Vanta Bioscience Ltd has a P/E of 132.3 and a return on equity of 0.87%.

What is the stock symbol of Vanta Bioscience Ltd?

Vanta Bioscience Ltd is listed on the BSE under the scrip code 540729.

How has Vanta Bioscience Ltd's share price moved over the past year?

Vanta Bioscience Ltd's share price is down 31.4% over one year and down 8.4% over three months. Its 52-week range is ₹14.71 to ₹26.22.

More on FinBizNet

Data as of 19 Nov 2026. Descriptive market data only — not investment advice.